Sabrina Johnson | President, CEO, Secretary & Director |
John A. Fair | Chief Strategy Officer |
Lisa Walters-Hoffert | CFO |
Good . My name is Joanne, and I will be your conference operator today. At this time, I would like to welcome everyone to the Dare Bioscience, Inc. Q2 2022 Conference Call. [Operator Instructions]. Ms. your begin may you conference. Johnson,
Good Wonderful. Second Dare welcome our and XXXX Thank Bioscience. Financial for you. Quarter Call Results to Update afternoon, and Business
Our our use XXXX. the quarter to review rest our our plan of strategy call milestones time to and anticipated business development the highlight last and discuss and since second May in our today is objectives results, review for
remind of you statements we federal that events Reform made discussion Private should risks like from those begin, could Before are of this during these forward-looking meaning are I that anticipated historical or Securities statements XXXX. will the implied provisions which be not within due unknown statements. laws, to the to safe the facts would securities include forward-looking and by to known Litigation pursuant statements or of of differ Any considered statements today's made and Act harbor materially call results uncertainties. Actual the
You undue reliance statements. forward-looking should not place on
law. XXXX. developments today, by as X, call new information of filed Forward-looking reflect information was the quarterly March XX-Q company's August call, out June any cautionary was XX-K the XX, after point undertakes that on their as which the annual and today. our XXXX, forward-looking XXXX, year XX, this except I statements to entirety Form on for would report includes XXXX, by statements filings, update including time-sensitive this which the ended SEC filed in of to current report to the December content no ended in on XX, our are also qualified or required that for statements like is Form obligation only quarter Dare
more lacking course, and, our also accelerate to that solely shareholders. families As women and shortcomings use sexual in including innovative not where a meaningful Why? compelling improve were and that exist, in compelling and belief led for ease drive form and has current expand impacting can set options or health. We but women outcomes seen Dare innovation differentiated that and is of you of these stakeholders, in broad of adoption. their is these convenient standard It women's the health therapeutic are health, options choices, where a not of care of product is work we health for but many good effective our enhanced partners factor women, squarely to prioritizing markets brands. for only Because commercially that fertility, has areas vaginal women's know, successful millions treatment contraception, focused have
look U.S. million ages There XX intervaginal are $XXX ring and contraceptive, million XX at first annual the in revenue. contraception. women the monthly at peaked to XX NuvaRing Let's
estimated what to to Mirena about contraceptive, at menopause? and market treatment. XX XX intrauterine hormone problem million the arousal system There enough billion. peaked $X.X billion first Premarin each releasing are the revenue. And women menopause new annual million seek have are There The first about postmenopausal at hormone in peaked significant therapy, estrogen entrants And arousal problems? $X how year, to
Now the sexual while women for FDA-approved no product first arousal to we since there yet, for can't success of disorder. point the is product female
and male become brands. Novel products analogous The first at to provide meaningful potential have sales. product $X that peaked for dysfunction, flexibility billion annual the features in condition erectile the Viagra new
in or big potential the novel health? candidates contraceptive Dare, ideas So our the candidates next Well, believe what are at portfolio. are these women's we X in
X% product, believe women, and health XACIATO, the DARE-RHX. portfolio, for hormone-free our gel, in contraceptive long-acting and bacterial programs vaginal administration. treatment The Ovaprene, system, vaginosis first hormone-free vaginal injectable a monthly our target in men vaginal a X first X- single-dose for reversible it's contraceptive We FDA-approved to first candidate, XX-month ADARE-XXX/XXX, clindamycin contraceptive phosphate DARE-LARCX,
cream active product arousal as designed being hormone the in or candidate, DARE-PTBX, intravaginal breast progesterone first DARE-HRTX, the product and therapy, therapy over cancer. with candidates ingredient the sexual in first progesterone the our product our and DARE-FRTX it's And ring product days. monthly portfolio, portfolio, receptor FSAD. with a health the IVR We first topical Viagra for treatment XX estradiol bioidentical release DARE-VVAX, believe our for hormone-free candidate positive women same to female first-in-category as candidate, management bioidentical potential hormone sexual Our and evaluated disorder vaginal atrophy pregnancy
over for use principles, options the continue candidates a or to new well-characterized on core the needs. compelling cost opportunities, pipeline first-in-category of lacking And shareholders. or diverse a market time great of looking that stakeholders, are well-known built first-line So And meaningful found as these our of broad outcomes investors for And the be including to The potential the with and for a first and is molecular portfolio compared Providers for of leverages the opportunity well-characterized yes, looking and that overall, opportunity. families our it's And yes, effective programs partners prioritizing and course, mitigate partners enhance strategic In active API. of help choices or good given mitigated therapeutic that patient ingredients example for execution FDA-approved often highly Dare good it's our a unmet women looking for are risk, core market and these with product for will of product and address women risk belief API and belief commercial seek are our them development XACIATO. to products. women's meaningful differentiated entities. diversified our first-in-category navigate in a product pipeline to the course their represent their potential health in convenient the portfolio principles a innovative and many to the a needs lifetime. of is preference that independent can women opportunities and overall line pharmaceutical case set XACIATO,
from to dollars that by well-characterized API, This while an Anyone allows in of entities. category. pathway Well, a category Phase have approaches XXX(b)(X) about for using her. that dosage XXX(b)(X) XACIATO, non-new for first-in-category They products care health duration us Phase the transactions health for advancing form versus improve delivery and delivery API knows for health in planned allow XX% and of And of regulatory lead is to Recent care. just let's for success development The transactions and probability in approval global has of following entities that XX% configure platforms that's outcomes. Persistent condition brands to use of new designed recent the brands. pathway. most that new health reminder transformational candidates has frequent consumers manage from that that possible evidenced for our most is success of X% XXX(b)(X) the differentiated I in to molecular the that women a good women's pharma are of approval XX% delivery differentiated a opportunity XX%, the value needs talk respectively, with advancing the creative household. often candidates. are to molecular been Why the women's commercial platforms. in multiple the III As relevant opportunity to unmet most can require a regulatory likelihood Novel us important?
today. evidenced programs call we to be our by We drive value initiation, a deliver focus our our of data include expect The achieve alone a in the to will forward continue our as we have milestones. product Phase anticipated milestones X to launch, III portfolio XXXX and readouts
of in Specifically, the phosphate terms for the clindamycin X% vaginal vaginosis. milestones, gel, XACIATO, bacterial
and targeted planned this the that year. We for quarter of launch have commercial fourth
symptoms. top arousal sizing, follow. So quarter of for study line the the That's breast year. anticipated data for fourth which more year disorder study atrophy Phase I/II Sildenafil treatment fourth an commencement quarter. data treatment data line interim study pending this in IIb a program, is for is that's planned and cancer. Cream, IDA planned the Phase menopausal hormone monthly this readouts our analysis women our the Phase the study data quarter line on therapy the process this That pivotal for DARE-HRTX, Phase the announcement about I/II year. that our anticipated study sexual with Ovaprene, is female target hormone-free of year; contraceptive, talked this to VVAX fourth were for one vaginal top top III program approval for
our milestones FDA. on regarding received we've and to provide shortly, commercialize I'll to call an John perspective of the program first, provide turn and particularly provide XACIATO some for with address to some Organon anticipated later IDE-related to So targeted an want update to over I the discussions as this year. to as collaboration with well launch on this update various year questions Ovaprene the on the the But
necessary year Phase targeting for FDA. study early premarket Ovaprene we're the have III to what single support study, be In the pivotal the mentioned, initiate I As to IDE expect commencement the to IDE this we must in We process FDA-approved in or place. Phase approval of a order XXXX. pivotal initiated to an we PMA submission III
FDA-approved device division there remember to no FDA the with in predicate product is may Ovaprene. a can of review that of Ovaprene existing There use the compare no You that the is Ovaprene. for device leading that FDA is
will PMA XXX(k) via a Ovaprene a such, submission. As and not be reviewed
certain We've characterization profile process discussing completed or the animal The our support recall months to discussions and of of conducted prepare be utilizing and study completing the Ovaprene clearly III subjects to to Based be and which Even with We cooperative that PMA into of contributed the development over FDA or so adequate. as use. the with more investigator NIH. to in of study, potential the such from would chemical over was be quarter can support FDA we terms FDA with Ovaprene, to XXXX, part and with process early Shriver couple a has look Those FDA. Kennedy Health time the communications or the on and I the commercialization approval a of the the step been last for following clearly fourth a the sheet you these studies the the the of via on the Health the and now can portfolio process will study the interactions process study Ovaprene Institute differentiated. is IDE NICHD, presubmission National agreement, pivotal continuing working While contraceptive. of is that company, of anticipate that years for and XXXX, on with a to to research a of seen forward also FDA payer sample process additional at study such FDA of the if to least discussions ongoing Ovaprene in approval, to ongoing months the under we the initiated means that, safety challenging may protocol Institute the FDA's demonstrated how biocompatibility, Development, which with X-month expect for Bayer differentiated been FDA the interactions Human it Ovaprene such also the with subject product. of and CRADA, XXX on several With other be and pivotal and and we've firsthand III we were it align IDE National John IDE, Eunice Child the collaborator We've the pleased Ovaprene first-in-category for we the on targeting commence quarter updates. regulatory are the development our study not that if with XX NIH benefit duration, than to for Phase Phase preparatory of collaborating the be of clearly novel the meeting size required these and use product will turn Bayer, this require based and research more product. will contraceptive differentiated third safety
Thanks, Sabrina.
and or these out-license believe of in in demonstrate via ultimately value upon the are our the portfolio on or such best and external categories, first Opportunity we therapeutic into assets generate dynamics avenue the collaboration its than to Dare attempting Given collaborations to to enter rather our XACIATO is and agreements the commercialize differentiated products potential current own. Ovaprene, stage developing first category. be to contingent market shareholders for that to commercialization specific line
me XACIATO. So begin product FDA-approved first vaginosis our let and bacterial with
be that natural is and which vaginal estimated anaerobic As strong our condition. we that positioned we've unique awareness on in sales. is to by to that received needed microbiome bacteria, for women vaginitis, up year. our vaginitis commercially and utilization also agreement cause is receive from to of to U.S. approximately impacted its balance this mentioned became XX And the million Organon, fourth calls, overgrowth advance differentiated U.S. vaginal health, of payment in and we bacterial license reaches vaginosis eligible on of we provider believe can focus including Organon available tiered odor result market in the of health, with of payments royalties net of common as will a The disrupts believe the based and symptoms impact uniquely most condition result cash commitment women such capabilities, shares We effective and an $XXX.X and to and women's quarter in $XX in June. million commercial of the well is previous to worldwide Organon innovations on the bacteria, patient to are XACIATO an women's a collaborator Gardnerella critically XACIATO bring as our milestone most XACIATO coupled the product after their expected characteristics. discharge. as Under the XACIATO, is to on commercialize XACIATO, license global XACIATO in drive unique potential double-digit and with based Organon ensure Organon's this million
While Organon, marketing, functional various teams, the commercial positive. collaboration, has the very are our team been with still in leadership overwhelmingly experience Organon including our and market really sales and access broader we early
and larger very the collaborating and Organon focused health the organization in have of driven their highly Organon into We commercial is accelerate brand franchise been our . women's with to integration XACIATO
in very into our XACIATO pleased be I position that of putting commercial but a the the substantive will provide with effort more team building better with We after product the assure to you organized launches, level brand. updates you is can
Bayer. contraceptive to whose commercial novel commercial transition underway U.S. So candidate are license with let Ovaprene, now monthly under for a hormone rights our me activities X agreement
advisory agreement reminder, commercialize week, full Bayer's with in of development Dare right to Ovaprene by of control As rights an million has and extensive license a Phase process. to $XX payment regulatory for XX resources Ovaprene, approximately capacity our part commercialization obtain commercialize while has over per as access the approval exclusive III a Bayer clinical, hours manufacturing Dare completion Dare. to pivotal following retains making overprints Bayer the in the study U.S. and the to to
tiered they're potentially Thereafter, a initiated contraception earlier, Dare is And entitled focused addition in form generic on commercial is actively with resonate as their without in without that predicate franchise, with and the totaling patients. that on including position Sabrina novel identifying will points to you of receive of payers, know best women leadership and and differentiation commercial of looking category Mirena royalties hormone-free to the $XXX net in position contraceptive to activities, uptake. sales. unique drivers and proactively way leadership providers Ovaprene and million with milestone FDA-approved the double-digit category has with maximize to engaging payments the an Ovaprene similar noted the team providers Many providers insights a key equivalent. hormonal Bayer Ovaprene. gain Bayer and is market meaningful to a a into pre-commercialization establish and and discussions has payers to position They uniquely payers, distinct are
is sufficient product has condition, the our be category. in for sexual Currently, are mentioned, version first a potential sexual the as inability is this the our and the investigational during only Turning characterized FDA-approved which Sildenafil means there Cream, condition product to disorder, attain dysfunction. FSAD genital really Sabrina to female which arousal erectile of FDA-approved Sildenafil or her maintain activity. to Cream by now no address to akin arousal physiological therapeutics to
clinical Phase few about treatment country. the in interest mentioned, FSAD XXXX, were in that initiation. the new so we started at evaluating was for Cream post a study Sildenafil RESPOND we As previously the first online inquiries IIb as The XX,XXX study the there study in the potential across overwhelming over months immediate sites
its evaluated want characteristics Sildenafil being as endpoints to to a can much responsive study, is IIb the we of the and Phase Cream. best first as women this most kind of positioned we to about As be learn
been As via to interviews partner periods. enrollment and criteria and cautious thoughtful subject a and such, screen relative her our exams, series of we've each medical characterizing
in study are many candidates more on continuing of investigational you are to be approved there that aware, this are believe optimal not are a We We place product, since approved, product. studies as IIb thousands the Phase with program be pace. than enroll women subjects the would at demands it's for expected otherwise an know, women if that will candidates for deliberate but of exceptional
study evaluate data after sizing, interval has and analysis which to analysis conduct line confidence this anticipated for a Our that trial trial. timing we on top protocol planned we'll this guidance provide in from expect the interim to the year,
IVR investigational, estradiol and bioidentical over our attention our XX-day DARE-HRTX, Turning therapy of to designed bioidentical or part progesterone regimen. a intervaginal a ring hormone as period continuously to deliver
the versions in over from positive women I months And you line and of Phase approximately study X approximately healthy X participating participated DARE-HRTX, a incidentally, study announced the dose of in first I/II in evaluate study. this may the start XXXX. April in open-label XX will I the Phase of PK Phase I announced DARE-HRTX the higher also consecutive of women we the recall, As results And use. study postmenopausal in we study study. new clinical top of lower that study XXXX, versions many Phase of first are same This in evaluated
with us some collect data, to addition and giving and data relief more efficacy. a data, this safety, of preliminary will usability, us study acceptability providing also symptom PK package In robust evidence
subsidiary so. financial study of the advantage in Australia previous doing being conducted clinical of benefits the to with take study, Australian this is through As and
I/II from Phase during of line to the quarter this report XXXX. expect top We fourth study data
Finally, can our DARE-VVAX. turn attention we to
approach risk to ideal at the considered in the vaginal to positive with VVA, of XX% between year as earlier not vulvar be investigational for it breast survivorships many noted, breast the important challenging estrogen-based in of I/II Hormone our program. history type very cancer first the and be standard mentioned, Currently, formulation for previously for are prescription million breast receptor postmenopausal by expect address patient option interventions. could in X.X important cancer candidates third women the to of this women this, first-in-class diagnosis Phase second treatment for as option half positive study of We initiated study for is a in year. As in cancer to and the this I/II Phase a nonhormonal year. VVA during have these addressing excuse VVA, cancer an more there survivors. new would top end women receptor products hormone -- of I and this quarter administration the report for prevalence an most have the the estimated or are DARE-VVAX of than for breast in U.S. data common in are line XXXX in cancer of of update the survivors me, you this for or we XXXX we later We'll Australia or And of population, new breast history FDA-approved of atrophy, very cancer like is breast a women. condition as a to no XX%. these tamoxifen provide and and proprietary this vaginal is
in Lisa maintains study of which I in updated a Organon, Phase with you position we Bayer, health, leader catalysts, for agreement update. now bacterial DARE-HRTX vaginosis, financial for in program. commercialization turn terms subject leadership with readouts contraceptive program, the U.S. is a Ovaprene, look FDA-approved who program our X our license first-in-category DARE-VVAX I/II XACIATO, pivotal a is a our collaboration contraception as of start treatment global the and to the our of forward provide in for a to call product the launch global women's data to near-term as well over who from to our will So keeping potential on
second like comprised and Thank for to June for or everyone, you, to Dare's Dare's quarter XX, would us I John, XXXX, business quarter of today. the refer model current joining now X will XXXX. of is the summarize results financial thanks, parts. quarter which I as ended the
advance to R&D address that identified and of assemble and health. portfolio this to investment acquisition product candidates or and a maintenance expenses. we've is includes required needs first corporate costs ongoing meaningful The and women's in portfolio The differentiated research do overhead, unmet that development
value to securing and one regulatory milestones near value second do model our time ways are of differentiated this and portfolio's over from the There payments product approach form license term. our long generate of royalties the fees, the monetizing part many and and The events and and clinical includes upfront over on involves net commercial products sales. with in outcomes of
this occurred fee second XXXX, global for agreement in closing of XACIATO due upfront license revenue the the our with of For Dare, we of quarter million when $XX during license the Organon. recognized from with connection
once As XACIATO current additional and my mentioned, the royalties entitled colleagues milestones will launched. back But have quarter. to to commercially be is Dare receive
and administrative general approximately million. G&A expenses or Our $X.X were
quarter-to-quarter comparable and actually Then Ovaprene. of license we million July, in ongoing Our affairs from $X.X Organon disbursement equivalents. a IIb period primarily ended current under approximately existing expenses in which approximately to trial and cash fee were vary additional regulatory our $XX $XX manufacturing, related the the activities payments less grant cash cash regulatory manufacturing program. DARE-LARCX the R&D the million million, reflected our to and of for million representing $X.X the cash million expenses, approximately and We received $XX based $X.X current Sildenafil portfolio about fund and quarter clinical with than the XXXX Phase on other and RESPOND Cream quarter's activities The of were preclinical clinical, cost million. R&D from
expected the in sales and and Dare agreement here thereafter, royalties, under future Again, upon entitled earlier, occur the net commercial of royalties receive eligible million net is with $X.X based on on be the to of XXXX. upon And XACIATO aggregate cash in Organon, up a quarter touched payment based license double-digit receive milestones we to launch in be sales. will to As the first will sale the developments. also our addition $XXX fourth other of to to million ongoing of sales commercial
highlighted tax $X.X calls, quarterly our years. and payment of grants, during in multiple The collaborations established importance is program sources grant include credits. of of part Now novel the to of larger we've our million strategy. to funding received the our nondilutive July finance development over DARE-LARCX These a
other from DARE-PTBX. addition, a grants have In NIH related we the in varying development received fund to amounts Ovaprene, and of and DARE-LARCX, the research NICHD market activities variety to and ADARE
studies. In the studies NIH currently allows to reimbursement expenses with receive pivotal NIH those expenses, Australia our of Australia, which partial we in terms the for in in is the did apply will cost experience And Dare extensive our finally, eligible and of collaborations, into being for the eligible our in continue conducted up with conducting also with R&D occurred to studies. Ovaprene of connection and to currently contraceptive XX% share the NIH's tap study
As of increase our candidates will to of advance million XXXX authorized capital endeavor to allow and XX.X our of proposal want and as to thank to you in opportunities creative, this other But collaborative August common stock in approximately annual had be X, outstanding. the recently will the of shares for before transactions potentially our we as common shares meeting necessary approved to in and in an that our future your years . approval build shareholders at We explore XXXX, multiple us arise. over shares pursue seeking closing, to stock using shareholder value. and opportunistic reiterate financing Dare
capital for the in to Form filed condition, was over well which like XX-Q year XX, annual as XX, ended the as I December more financial review the our ended which on filed our turn the our for quarter XXXX. questions. to XXXX, back XX, We would for of discussion also March encourage to XX-K investors Form operator call report 'XX, factors and detailed resources was risk financials, liquidity, our the June today, on now
[Operator from the Wainwright. Instructions]. And of your first comes Tsao with Douglas line H.C. question
from Raja with Markets. Your the Capital next comes Kumar question of line Brookline
the safety are for insights the profile? share Whatever Like any can Can I'm Kumar. trial? you patients updates how you share? responding, regarding the
So we're I/II And that atrophy in our looking trial. the what is to our perspective at VVAX is, in now you just that's trial study on right, what little program. that more right for a going Australia Phase trial on vaginal give and maybe
regimen, treatment of is studying that actually interesting a is all, why used estrogen a antagonist delivered part which active is chemical known reason in is And case cancer vaginally. being the in It of the first breast, this that I mentioned but a has that that So we're a breast case vaginally. in tamoxifen, as entity, often as earlier, -- is really tamoxifen an as profile. the acts an estrogen agonist
tamoxifen, they there study the using that important prior and been necessarily looking some got vaginal showed us published this specifically formulated in What run about makes Phase a they So vaginally not was it at for but and proof-of-concept improvements. study a that proof-of-concept optimally that's condition. excited tamoxifen just to delivered really it to study, opportunity. actually a the really was entity consider I/II interesting chemical And was
in pH. improvements they So showed vaginal
vaginal often the microbiome. also in So other to vaginal dryness. vaginal challenges with that's can And pH one and rises, of terms lead atrophy, complications improvement of the vaginal that in the
is with of have study, breast a optimize women, cancer. at -- women done history a exciting this of cohort worked And to so obviously treatment number And women groups. that we And including actually we're then since looking what a actually looking I/II study, at in we're formulation. Phase really different proof-of-concept the of
placebo. different levels X dose looking and we're So at
is a intravaginally women for And describe a in will for week sort then X able comes all to treatment of following for product, They it X and days. weeks period these be it. weeks so first to a once total the best twice day XX gel the way a self-administer the vaginal cap the self-administered of
So be we'll get analysis, will And question period your of part some of of the over that then sharing. what time. we nice to data
a very pharmacokinetics, obviously is looking that traditional tolerability. We'll you it I take at would safety at with of the part we'll kind and be Phase of study. kind So of approach be any looking
of So vaginal than well just effects for look orally. formulation. administered a look lower we're using the again, well, preliminary that But looking as endpoints will secondary vaginally, because at this much as as the what's any administered is we're sort systemically really you as efficacy of well. dose typically But safety the
terms a of In things. couple of
So symptom bothersome what we in most the is. are Phase us tell study to women these asking I/II their
the is dryness So for it some women, some painful for intercourse. women, it's
enroll symptom them the when with is women. these we are most their because they study symptomatic in asked So have bothersome
So see changes like the we that vaginal And at things be will vaginal kind are was looking which really run, of atrophy. study if managing looking symptoms. any will important and in then determinants success proof-of-concept cytology that PH, to be in bothersome importantly, similar of most we to
women, that's the powered not how to So It's per doing product. se. are study. why for they're be of really it's a But sense on Phase nice should symptomatic we efficacy because all I/II these a able really get
of the data able the be fourth data top line that readout do the when we'll to are report those So quarter. kind we in
helpful a was question. answer to that hopefully, So your
the have to the provide in trial? to how it? regarding -- you question plan sites to do do one many rate the Like more like ongoing enrollment And One could HRTX some -- sites you color more you activated? add of
Yes.
for is I/II So study Phase is therapy. the similarly, vaginal our -- evaluating trial, a hormone HRTX and ring
to a that because completed we've relevant out completed I already is I couple question ways. already simply which Phase a of study, study your We the have point
importantly, both know those to all, as vasomotor dose of completed -- first looked of levels study the demonstrated menopause well atrophy vaginal already as really profile already the the So we and be we the potential demonstrated symptoms PK in therapeutic because HRTX with that's its the hormones. effective at been of
And demonstrated. we so for actually with vaginal already XX-day study use wanted has that in a a been months What give is opportunity an to to the row product women do in ring. this X
X X the use all get X different it X again. looking we the of XX she'll over same are postmenopausal. X, are So and rings women. course They times, at months, doses It's about to different
that women are these again, menopause. in So are
VVAX data. study, well symptom the looking with about we'll talked release at as I be usability, what to similarly safety, so acceptability And as
before most them very we're we're how going they're of after about the ask asking come months doing, X then using their they similarly, of So bothersome in symptoms and them product. to menopause
give signs. some but not us again, powered for efficacy, So nice will
we terms a right, Phase I sites, do Australia, Australian studies few the very not we effective, huge. cash rebate. in number of have Australia is our of actually cost And the site, In a of and because R&D
we in quite gosh, asked few a have interesting, the the the as work so sites. sites can't. says women is we we Australia, But in they across you study, at "My what And his that of and Phase same think who our end about of it study. No, with just I product we lot mentioned notified So said, John a comments, found studies -- it's future to the had been be can't in prior using asked the I keep any this? that
they were because Phase experience had participants prior many study the prior product in with -- of in the So I study. this the already
to don't we sites. need add any So additional really
So data trial, as mentioned, at then subjects following and quarter. in we I that line readout the top in point, this the expect, we're the fourth
for remarks. questions. There to Ms. the over turn Instructions]. further back call [Operator closing no are will Johnson I now
Great. we those compelling there development we of where expand shareholders. you our really various we've therapies care compelling where we hear commercially the commitment differentiated the adoption quarter ease more all the FDA-approved opportunities. health really women, and prioritize stages much areas for use vaginal portfolio, options expected our the time of are enhance launched X in stakeholders, women's in where fourth and the this shortcomings to factor of health our candidates X can primarily have market our discussing product health the outcomes With sexual bring taking not and be of for diverse recent Well, of seek drive care women, treatment updates thank year. to standard value think well-being afternoon this contraception, improve form a to drive that has and and to for prescription current about as where and ongoing the exist, been and facility providers so health, and to meaningful of Today, market in
candidates XACIATO Organon you our progress XXXX launch. our the activities forward to keeping the under for objectives regarding important against So we all as updated we on well with of milestones set and look development as the
into tuning for of you and thank today your call the all for So support.
This call. conference today's concludes
disconnect. now may You